<DOC>
	<DOCNO>NCT01660633</DOCNO>
	<brief_summary>The purpose trial confirm safety efficacy high-dose Melphalan HCL Injection ( Propylene Glycol-Free ) myeloablative condition regimen multiple myeloma patient ( MM ) undergo autologous transplantation .</brief_summary>
	<brief_title>Safety Efficacy Study High Dose Melphalan HCL Injection ( Propylene Glycol-Free ) Myeloablative Conditioning Multiple Myeloma Patients Undergoing Autologous Transplantation</brief_title>
	<detailed_description>The sponsor current study , Ligand Pharmaceuticals Inc. ( Ligand ) , previously CyDex Pharmaceuticals , Inc. ( CyDex ) , develop Melphalan HCL Injection ( Propylene Glycol-Free ) orphan drug product use high dose conditioning treatment prior hematopoietic progenitor ( stem ) cell transplantation . This new injectable form melphalan HCL incorporate Captisol® , β cyclodextrin sulfobutyl ether sodium salt ( also know [ SBE ] 7m-β-CD ) , product . Captisol present facilitate use aqueous diluent ( normal saline ) reconstitution administration freeze-dried product place propylene glycol-ethanol diluent necessary currently use melphalan intravenous product . Captisol provide solubilization improve stability aqueous reconstitute diluted infusion solution . This second two study support product registration . This study multicenter study high-dose Melphalan HCL Injection ( Propylene Glycol-Free ) conduct 60 patient symptomatic MM qualify autologous stem cell transplantation ( ASCT ) . During Study Period , patient receive 100mg/m2 either Melphalan HCL Injection ( Propylene Glycol-Free ) Day -3 Day -2 total dose 200mg/m2 . Blood sample ( 5 timepoints post infusion ) population pharmacokinetic ( PK ) evaluation withdrawn indwell i.v . cannula first day administration melphalan ( Day -3 ) patient additional blood sample ( 2 timepoints post infusion ) drawn subset patient second day melphalan administration ( Day -2 ) . Following one day rest high dose myeloablative conditioning ( Day -1 ) , patient receive autologous graft ( Day 0 ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients symptomatic MM base IMWG guideline require treatment eligible ASCT . Patients 70 year age young time transplant . Patients older 70 year age may enrol casebycase basis patient meet local institutional criterion receive total melphalan dose 200 mg/m2 condition regimen approve medical monitor . Patients adequate autologous graft , define unmanipulated , cryopreserved , peripheral blood stem cell graft contain least 2 × 106 CD34+ cells/kg base patient body weight . Patients adequate organ function measure : Cardiac function : Left ventricular ejection fraction rest &gt; 40 % ( document within 8 week prior Day 3 ) . Hepatic function : Bilirubin &lt; 2 × upper limit normal alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &lt; 3 × upper limit normal . Renal function : Creatinine clearance &gt; 40 mL/minute ( measure calculated/estimated ) . Pulmonary function : Carbon monoxide diffuse capacity ( DLCO ) correct hemoglobin ( Hgb ) , forced expiratory volume 1 second ( FEV1 ) , force expiratory vital capacity ( FVC ) , oxygen saturation &gt; 92 % room air ( document within 4 week prior Day 3 ) . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Patients smolder MM require therapy . Patients plasma cell leukemia . Patients systemic amyloid light chain amyloidosis . Patients uncontrolled hypertension . Patients active bacterial , viral , fungal infection . Patients life expectancy &lt; 6 month . Patients prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent &gt; 5 year previously allow . Cancer treat curative intent &lt; 5 year previously allow unless approve medical monitor . Female patient pregnant breastfeeding . Female patient childbearing potential unwilling use adequate contraceptive technique 3 month follow study treatment Melphalan HCl Injection ( Propylene GlycolFree ) . Patients seropositive Human Immunodeficiency Virus ( HIV ) . Patients unwilling provide informed consent . Patients receive concurrent anticancer therapy ( include chemotherapy , radiation , hormonal treatment , immunotherapy , exclude corticosteroid ) within 30 day prior ASCT plan receive treatment prior Day +30 . Patients concurrently participate clinical study involve ASCT . Patients hypersensitive intolerant component study drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>High-Dose Melphalan</keyword>
	<keyword>Propylene Glycol-Free</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
	<keyword>Captisol</keyword>
</DOC>